Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus.
The broad spectrum of antiviral activity of ribavirin (RBV) lies in its ability to inhibit IMP dehydrogenase, which lowers cellular GTP. However, RBV can act as a potent mutagen for some RNA viruses. Previously we have shown a lack of correlation between antiviral activity and GTP repression for Hantaan virus (HTNV) and evidence for RBV's ability to promote error-prone replication. To further explore the mechanism of RBV, GTP levels, specific infectivity, and/or mutation frequency was measured in the presence of RBV, mycophenolic acid (MPA), selenazofurin, or tiazofurin. While all four drugs resulted in a decrease in the GTP levels and infectious virus, only RBV increased the mutation frequency of viral RNA (vRNA). MPA, however, could enhance RBV's mutagenic effect, which suggests distinct mechanisms of action for each. Therefore, a simple drop in GTP levels does not drive the observed error-prone replication. To further explore RBV's mechanism of action, we made a comprehensive analysis of the mutation frequency over several RBV concentrations. Of importance, we observed that the viral population reached a threshold after which mutation frequency did not correlate with a dose-dependent decrease in the level of vRNA, PFU, or [RTP]/[GTP] (where RTP is ribavirin-5'-triphosphate) over these same concentrations of RBV. Modeling of the relationship of mutation frequency and drug concentration showed an asymptotic relationship at this point. After this threshold, approximately 57% of the viral cDNA population was identical to the wild type. These studies revealed a lethal threshold, after which we did not observe a complete loss of the quasispecies structure of the wild-type genome, although we observed extinction of HTNV.
Chung
Dong-Hoon
DH
Department of Biochemistry and Molecular Biology, 2000 9th Avenue South, Southern Research Institute, Birmingham, AL 35205, USA.
Sun
Yanjie
Y
Parker
William B
WB
Arterburn
Jeffrey B
JB
Bartolucci
Al
A
Jonsson
Colleen B
CB
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002522:Chlorocebus aethiops; D004305:Dose-Response Relationship, Drug; D005787:Gene Frequency; D016679:Genome, Viral; D006160:Guanosine Triphosphate / Q000378:metabolism; D018063:Hantaan virus / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism*; D009154:Mutation; D009173:Mycophenolic Acid / Q000378:metabolism; D016566:Organoselenium Compounds / Q000494:pharmacology; D012367:RNA, Viral / Q000737:chemistry; D012254:Ribavirin / Q000031:analogs & derivatives / Q000494:pharmacology*; D012263:Ribonucleosides / Q000494:pharmacology; D014709:Vero Cells
D000998:Antiviral Agents; D016566:Organoselenium Compounds; D012367:RNA, Viral; D012263:Ribonucleosides; D012254:Ribavirin; D006160:Guanosine Triphosphate; D009173:Mycophenolic Acid; C039064:selenazofurin; C033706:tiazofurin
Virology. 1981 Apr 30;110(2):281-9
6111860
Antimicrob Agents Chemother. 2007 Jan;51(1):84-8
17060520
Antimicrob Agents Chemother. 1983 Sep;24(3):353-61
6615611
Arch Virol. 1983;77(2-4):223-9
6639357
J Infect Dis. 1983 Dec;148(6):1005-12
6140290
Antimicrob Agents Chemother. 1984 Oct;26(4):476-80
6151377
Antiviral Res. 1985 Feb;5(1):29-37
3985606
Arch Virol. 1985;84(3-4):197-206
2859845
J Infect Dis. 1986 Mar;153(3):489-97
2869089
Antimicrob Agents Chemother. 1986 Jun;29(6):1010-6
3015012
Virology. 1986 Dec;155(2):633-43
3024404
Rev Infect Dis. 1989 May-Jun;11 Suppl 4:S750-61
2546248
Prog Med Virol. 1989;36:62-102
2573914
J Infect Dis. 1991 Dec;164(6):1119-27
1683355
Antiviral Res. 1993 Sep;22(1):45-75
8250543
Emerg Infect Dis. 1997 Apr-Jun;3(2):95-104
9204290
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1492-7
9990051
J Virol. 2005 Feb;79(3):1943-7
15650220
Virus Res. 2005 Feb;107(2):129-39
15649559
Virus Res. 2005 Feb;107(2):173-81
15649563
Virus Res. 2005 Feb;107(2):215-28
15649567
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4448-52
15767582
Antiviral Res. 2005 Jul;67(1):38-45
15919121
Virology. 2005 Jul 20;338(1):1-8
15939449
Nat Med. 2000 Dec;6(12):1375-9
11100123
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6895-900
11371613
J Virol. 2001 Sep;75(17):8074-81
11483752
J Virol. 2001 Oct;75(20):9723-30
11559805
Clin Infect Dis. 2002 May 1;34(9):1224-31
11941549
Antivir Chem Chemother. 2001 Nov;12(6):327-35
12018677
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12938-43
12215495
J Virol. 2003 Jan;77(1):481-8
12477853
Panminerva Med. 2003 Mar;45(1):43-51
12682619
BioDrugs. 2003;17(3):169-77
12749753
Drug Resist Updat. 2004 Feb;7(1):19-24
15072768
Annu Rev Microbiol. 2004;58:183-205
15487935
Science. 1972 Aug 25;177(4050):705-6
4340949
Proc Natl Acad Sci U S A. 1973 Apr;70(4):1174-8
4197928
Antimicrob Agents Chemother. 1977 Jun;11(6):946-51
879760
PLoS Comput Biol. 2005 Nov;1(6):e61
16322763
J Virol. 2006 Jan;80(1):20-6
16352527
J Biol Chem. 1982 Jun 25;257(12):6867-70
7085610